Clinical trial NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Official title: A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Solid Tumor
Colorectal Cancer
Cholangiocarcinoma
Bladder Cancer
Ovarian Cancer
Gastric Cancer
Palpable Subcutaneous Malignant Lesions
Renal Cell Carcinoma
Melanoma
Epithelial Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
Lead sponsor: Toray Industries, Inc
Sponsor class: INDUSTRY
First posted: 2019-03-13
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.

Detailed description: This study is an open-label, Phase 1b study evaluating TRK-950 in combination with 1) FOLFIRI or 2) Gemcitabine / Cisplatin or 3) Gemcitabine / Carboplatin or 4) Ramucirumab/Paclitaxel or 5) PD1 inhibitors (Nivolumab or Pembrolizumab) or 6) Imiquimod Cream for subcutaneous lesions 7) Bevacizumab 8) Gemcitabine / Carboplatin / Bevacizumab, 9)PLD, 10) Carboplatin / PLD / Bevacizumab or 11) Paclitaxel in Patients with Selected Advanced Solid Tumors. The objectives of this study are to determine the safety, tolerability, MTD, recommended Phase 2 dose (RP2D), PK, and preliminary anti-tumor activity of TRK-950 when used in combination with other treatment regimens.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed solid malignancy for which the following treatment regimens are warranted:
* Arm A. Colorectal Cancer with no prior history of treatment with Irinotecan alone or in combination: FOLFIRI as standard of care
* Arm B. Cholangiocarcinoma, Bladder Cancer with no prior history of treatment with Gemcitabine alone or in combination: Gemcitabine / Cisplatin as standard of care
* Arm C. Ovarian Cancer who have relapsed at least 6 or more months after completion of a previous platinum-based therapy and have no prior history of treatment with gemcitabine alone or in combination: Gemcitabine / Carboplatin as standard of care
* Arm D. Gastric Cancer including Gastroesophageal Junction with no prior history of treatment with Ramucirumab, Paclitaxel or any Taxane class drug: Ramucirumab / Paclitaxel as standard of care
* Arm E. Solid Tumors: Eligible for PD1 Inhibitor (Nivolumab or Pembrolizumab) monotherapy as standard of care according to the approved drug label by the relevant regulatory authority
* Arm F. Locally advanced or metastatic disease in a cancer with at least one palpable subcutaneous malignant lesion (≤ 2 cm in diameter) for treatment with TRK-950 and Imiquimod cream (US Sites Only)
* Arm G. Renal Cell Carcinoma with no prior history of treatment with Bevacizumab alone or in combination: Bevacizumab for use in a fourth line or later treatment
* Arm H. Melanoma patients who progressed while taking Nivolumab, Pembrolizumab, or Ipilimumab, within the last 6 months prior to cycle 1 day 1
* Arm J. Colorectal Cancer patients who progressed on FOLFIRI or any other Irinotecan-containing therapy regimen within the last 6 months prior to cycle 1 day 1
* Arm K. (US Sites Only). Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer with ≤ 2 prior treatment lines who have recurred \> 6 months after most recent platinum-based chemotherapy and who are eligible for gemcitabine, carboplatin, and Bevacizumab as standard of care for dosing of TRK-950
* Arm O. Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer with ≤ 5 prior treatment regimens, as defined below and who are eligible for topotecan or pegylated liposomal doxorubicin as standard of care for dosing of TRK-950

  * Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response, and then progressed between 3 months and less than or equal to 6 months after the last date of platinum.
  * Patients who have received 2 to 5 lines of prior therapy must have received at least 4 cycles of platinum and then progressed within 6 months after the date of the last dose of platinum.
  * Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines of therapy
* Arm Q. Gastric Cancer including GEJ cancer with only 1 prior treatment regimen, which recurred during or within 4 months after frontline treatment, and no prior history of treatment with Ramucirumab, Paclitaxel or any Taxane class drug for metastatic disease: eligible to receive Ramucirumab/Paclitaxel as standard of care
* Arm R. Clear cell renal cell carcinoma with no prior history of treatment with Bevacizumab alone or in combination: Bevacizumab for use in a fourth line or later treatment.
* Arm S. Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer with ≤ 2 prior treatment lines who have recurred \> 182 days after most recent platinum-based chemotherapy and who are eligible for carboplatin, PLD, and bevacizumab as standard of care

  * The histological subtypes of the carcinoma that qualify for enrollment include serous adenocarcinoma, endometrioid adenocarcinoma, carcinosarcoma of the ovary, or adenocarcinoma not otherwise specified (NOS)
  * Patients with or without the breast cancer susceptibility 1/2 (BRCA1/2) mutations are eligible, provided that patients with the BRCA1/2 mutations have previously received PARP inhibitor treatment
* Arm T. Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer with ≤ 5 prior treatment regimens, or as defined below, and who are eligible for paclitaxel as standard of care

  * Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (complete response/remission (CR) or partial response/remission (PR), and then progressed between 90 days to less than 183 days after the last date of platinum.
  * Patients who have received multiple lines of platinum therapy must have progressed on the latest platinum, or within 183 days after the date of the last dose of the latest platinum
  * Patients with or without the BRCA1/2 mutations are eligible, provided that patients with the BRCA1/2 mutations have previously received PARP inhibitor treatment
  * Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines of therapy
  * The histological subtypes of the carcinoma that qualify for enrollment include serous adenocarcinoma, endometrioid adenocarcinoma, carcinosarcoma of the ovary, or adenocarcinoma not otherwise specified (NOS)
* Primary or metastatic tumors measurable per RECIST v1.1 on CT scan or by calipers (subcutaneous lesions)
* Karnofsky performance of ≥70
* Life expectancy of at least 3 months
* Age ≥ 18 years
* Signed, written IRB-approved informed consent

Exclusion Criteria:

* Laboratory values or medications that are contraindicated in the selected standard of care treatment regimens
* New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG
* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Prophylactic antibiotics are acceptable.
* Pregnant or nursing women
* Treatment with radiation therapy within 2 weeks, or treatment with surgery, chemotherapy, immunotherapy, targeted therapy or investigational therapy within four weeks prior to initiation of study treatment (6 weeks for nitrosoureas or mitomycin C, and 2 weeks or 5 half-lives whichever is longer for TKIs).
* Unwillingness or inability to comply with procedures required in this protocol
* Known active infection with HIV, hepatitis B, hepatitis C
* Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor
* Patients who are currently receiving any other investigational agent
* Any contraindicated condition or drug which would make the patient ineligible for the respective treatment regimen that is to be used in combination with TRK-950 (for example, autoimmune disorders for nivolumab or pembrolizumab treatment) as described in the Full Prescribing Information

Primary outcomes:
measure: Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0
timeFrame: through study completion, an average of 1 year
measure: Frequency of patients experiencing adverse events of special interest (AESIs)
timeFrame: through study completion, an average of 1 year
measure: Blood pressure
timeFrame: through study completion, an average of 1 year
measure: Heart rate
timeFrame: through study completion, an average of 1 year
measure: Respiratory rate
timeFrame: through study completion, an average of 1 year
measure: Temperature
timeFrame: through study completion, an average of 1 year
measure: Weight
timeFrame: through study completion, an average of 1 year
measure: Height
timeFrame: through study completion, an average of 1 year
measure: Performance status using Karnofsky performance status criteria
timeFrame: through study completion, an average of 1 year
measure: QTc interval determined from 12-lead Electrocardiogram
timeFrame: through study completion, an average of 1 year
measure: QRS interval determined from 12-lead Electrocardiogram
timeFrame: through study completion, an average of 1 year
measure: Frequency of patients with laboratory abnormalities (Complete Blood Count, Coagulation, Urinalysis and Serum Chemistry)
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Overall response rate (ORR)
timeFrame: through study completion, an average of 1 year
measure: Disease Control Rate (DCR)
timeFrame: through study completion, an average of 1 year
measure: Serum concentration of TRK-950
timeFrame: through study completion, an average of 1 year
measure: Plasma concentration of Gemcitabine for the first six patients in Arm K
timeFrame: At the beginning of Cycle 1 and Cycle 4 (each cycle is 21 days)
measure: Plasma concentration of Carboplatin for the first six patients in Arm K
timeFrame: At the beginning of Cycle 1 and Cycle 4 (each cycle is 21 days)
measure: Serum concentration of Bevacizumab for the first six patients in Arm K
timeFrame: At the beginning of Cycle 1, Cycle 2, Cycle 4 and Cycle 5 (each cycle is 21 days)
measure: Plasma concentration of PLD for the first six patients in Arm O
timeFrame: At the beginning and middle of Cycle 1 and Cycle 3 (each cycle is 28 days)
measure: Serum concentration of Ramucirumab for the first six patients in Arm Q
timeFrame: At the beginning and middle of Cycle 1 and Cycle 4 (each cycle is 28 days)
measure: Plasma concentration of Paclitaxel for the first six patients in Arm Q
timeFrame: At the beginning of Cycle 1 and Cycle 4 (each cycle is 28 days)
measure: Serum concentration of Bevacizumab for the first six patients in Arm R
timeFrame: At the beginning and middle of Cycle 1 and Cycle 4 (each cycle is 28 days)
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: HonorHealth Research Institute
state: Arizona
city: Tucson
country: United States
facility: AOA-HOPE
state: Arizona
city: Los Angeles
country: United States
facility: USC Norris Comprehensive Cancer Center
state: California
city: Newport
country: United States
facility: HOAG Memorial Hospital Presbyterian
state: California
city: New Orleans
country: United States
facility: Ochsner Clinic Foundation
state: Louisiana
city: Morristown
country: United States
facility: Atlantic Health System
state: New Jersey
city: New York
country: United States
facility: Perlmutter Cancer Center at NYU Langone
state: New York
city: Eugene
country: United States
facility: Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center)
state: Oregon
city: Portland
country: United States
facility: Northwest Cancer Specialists
state: Oregon
city: Dallas
country: United States
facility: Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center
state: Texas
city: Fort Worth
country: United States
facility: Texas Oncology - Downtown Fort Worth Cancer Center
state: Texas
city: Leesburg
country: United States
facility: Virginia Cancer Specialists, PC
state: Virginia
city: Milwaukee
country: United States
facility: Medical College of Wisconsin
state: Wisconsin
city: Lyon
country: France
facility: Centre Léon Bérard
Study officials:
References: